Q-omics provides the consensus-scored CXorf38 profile across patient tissues and cancer cell-line models. CXorf38 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, CXorf38 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, CXorf38 RNA expression shows 19,841 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, KIRC, and ACC as cancer lineages where CXorf38 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CXorf38 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CXorf38 survival associations across molecular data types. CXorf38 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CXorf38 RNA expression–survival associations across cancer types. High CXorf38 expression shows unfavorable associations in ACC, PAAD and UVM, but favorable associations in BLCA, SKCM and KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for CXorf38 RNA expression.
This table summarizes CXorf38 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CXorf38. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CXorf38 shows lower tumor expression in THCA and higher tumor expression in KIRC, HNSC, COAD, STAD and LIHC. The KIRC box plot shows higher CXorf38 RNA expression in tumor versus normal tissue (log2 FC = +0.752, t-test p < 0.001).
This table shows molecular features associated with CXorf38 in patient tissues and cancer cell lines. In patient samples, CXorf38 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CXorf38 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and CNS.
